Iodixanol

證據等級: L5

預測適應症: 3 個

Iodixanol: From Diagnostic Contrast Imaging to Osteoarthritis Susceptibility

One-Sentence Summary

Iodixanol is a non-ionic, iso-osmolar iodinated contrast medium used for diagnostic imaging, with no marketed therapeutic indication on record in this dataset. The TxGNN model predicts a possible link to Osteoarthritis Susceptibility, but this top-ranked prediction currently has zero supporting clinical trials and zero literature citations, and the only literature found for closely related terms (osteoarthritis, rheumatoid arthritis) describes iodixanol’s use as an imaging/research tool, not as a therapeutic agent.

Quick Overview

Item	Content
Original Indication	Not a therapeutic indication — iodixanol is a non-ionic, iso-osmolar iodinated radiographic contrast agent used for diagnostic imaging; no approved/marketed indication is on record
Predicted New Indication	Osteoarthritis susceptibility
TxGNN Prediction Score	99.16%
Evidence Level	L5 (model prediction only, no supporting studies)
US Market Status	Not Marketed
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data for iodixanol is not available (blocking data gap). Based on known information, iodixanol is a contrast medium — its pharmacology is limited to physicochemical properties (iso-osmolality, non-ionic dimer structure) that make it visible on CT/radiographic imaging; it has no known receptor, enzyme, or pathway target relevant to disease treatment.

Reviewing the actual evidence attached to this candidate makes the prediction’s basis clear: the literature returned under “osteoarthritis” (7 papers, see below) is entirely composed of imaging and biomechanics studies that use iodixanol as a diffusible tracer to study cartilage permeability and joint imaging technique — not studies testing iodixanol as a treatment for osteoarthritis. Similarly, the single paper under “rheumatoid arthritis” is a case report about desensitization to a different contrast agent (iohexol) in a patient who happened to have RA-related amyloidosis, again unrelated to therapeutic use.

This pattern strongly suggests the TxGNN score reflects knowledge-graph co-occurrence (iodixanol frequently appears alongside “cartilage” and “osteoarthritis” in imaging-research contexts) rather than a genuine treat-relationship. For the top-ranked prediction, “osteoarthritis susceptibility,” there is no evidence at all — not even this kind of indirect, non-therapeutic literature — making it the weakest of the three ranked candidates in this evidence pack.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available for the top-ranked prediction (osteoarthritis susceptibility).

The evidence pack also scored two closely related terms, both with the same L5/Hold status. Their literature is included here for transparency, since it explains the apparent knowledge-graph signal:

Osteoarthritis (TxGNN score 99.07%, rank 20119) — 7 papers, all describing iodixanol as an imaging/research reagent, not a treatment:

PMID	Year	Type	Journal	Key Findings
40155520	2025	Imaging/Technical	Annals of Biomedical Engineering	Dual-contrast photon-counting CT for assessing articular cartilage health
39012563	2024	Imaging/Technical	Annals of Biomedical Engineering	Nanoparticle diffusion CT/finite element study of cartilage function
28063646	2017	Ex vivo biomechanics	Journal of Biomechanics	Uses iodixanol (~1550 Da) as a neutral diffusing CT contrast agent to study osteochondral interface permeability
28518064	2017	Ex vivo biomechanics	Journal of Visualized Experiments	Protocol for tracking neutral/charged solute transport across cartilage
27793406	2016	Ex vivo biomechanics	Journal of Biomechanics	Finite element model of solute transport across the osteochondral interface
30374787	2018	In vitro	Journal of Experimental Orthopaedics	Iodine contrast agents do not affect platelet-rich plasma function in vitro
30145230	2018	Animal ex vivo biomechanics	Osteoarthritis and Cartilage	Aging effects on mandibular condylar cartilage stiffness (uses contrast-based diffusion imaging)

Rheumatoid arthritis (TxGNN score 99.00%, rank 21444) — 1 paper, unrelated to treatment:

PMID	Year	Type	Journal	Key Findings
36628042	2022	Case report	Cureus	Desensitization to contrast agent iohexol (not iodixanol) in a patient with RA-related amyloidosis; concerns contrast allergy management, not RA therapy

Safety Considerations

Please refer to the package insert for safety information. (Key warnings, contraindications, and drug-interaction data for iodixanol were not available in this dataset — TFDA label data is a blocking gap.)

Conclusion and Next Steps

Decision: Hold

Rationale: All three ranked predictions (osteoarthritis susceptibility, osteoarthritis, rheumatoid arthritis) are Evidence Level L5 with no clinical trials and no therapeutic-use literature. The available literature indicates iodixanol’s association with these disease terms stems from its use as an imaging/research contrast agent, not from any demonstrated therapeutic effect — there is currently no biological plausibility supporting repurposing.

To proceed, the following is needed:

TFDA/FDA label data (warnings, contraindications) — currently a blocking data gap
Confirmed mechanism of action (MOA) data from DrugBank or primary literature
Any preclinical or pharmacological studies testing iodixanol as a therapeutic (not diagnostic) agent in osteoarthritis or rheumatoid arthritis
Re-evaluation of the TxGNN prediction methodology to filter out non-therapeutic co-occurrence signals (e.g., drug-as-research-tool literature) for contrast media and similar diagnostic agents
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.